TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
LUNG

Pulmonx Corp

Healthcare · Medical Devices · —

2.10$ +4.5% vs. previous close Closing price · As of: Sep 18, 2026

Ownership

Ownership Structure

Who owns Pulmonx Corp (LUNG)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 87.6% of the shares are freely tradable; institutional investors hold 79.1%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 79.1%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 4.9%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 87.6%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 2.7%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 43Mio.

Largest Shareholders

Institutions

Institutions LUNG
Name Stake (%) Shares Change (%) Date
PRIMECAP Management Company 10.74 4,612,331 -2.4 06/30/2026
Morgan Stanley - Brokerage Accounts 9.30 3,993,562 -4.0 03/31/2026
Soleus Capital Management, L.P. 6.49 2,788,323 +0.0 06/30/2026
BlackRock Inc 6.20 2,661,607 -1.6 03/31/2026
ExodusPoint Capital Management, LP 4.53 1,943,834 -0.4 03/31/2026
Vanguard Capital Management, LLC 3.81 1,634,264 +0.0 03/31/2026
Bank of America Corp 2.72 1,166,826 +60.3 03/31/2026
Deutsche Bank AG 2.71 1,163,678 +3.4 03/31/2026

Funds

Funds LUNG
Name Stake (%) Shares Change (%) Date
PRIMECAP Odyssey Aggressive Growth 8.39 3,602,001 +0.0 06/30/2026
Vanguard MStar Total Stk Mkt Idx Invest 2.68 1,152,272 +0.0 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider holdings

Insider holdings LUNG
Person Role Shares Value As of Type
French Glendon E. III President and CEO 1,137,936 2,389,666 $ Sep 1, 2026 direct
Rose Geoffrey Beran Chief Commercial Officer 449,832 944,647 $ Sep 1, 2026 direct
Lehman David Aaron General Counsel 361,827 759,837 $ Sep 1, 2026 direct
Radhakrishnan Srikanth Chief Science & Techn. Officer 316,994 665,687 $ Sep 1, 2026 direct

Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.

Insiders

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
Sep 1, 2026 Radhakrishnan Srikanth Chief Science & Techn. Officer Sell 5,863 2.26 13,250
Sep 1, 2026 Radhakrishnan Srikanth Chief Science & Techn. Officer Sell 3,618 2.26 8,177
Sep 1, 2026 Radhakrishnan Srikanth Chief Science & Techn. Officer Sell 2,121 2.26 4,793
Sep 1, 2026 Radhakrishnan Srikanth Chief Science & Techn. Officer Sell 2,643 2.26 5,973
Sep 1, 2026 French Glendon E. III President and CEO Sell 37,784 2.26 85,392
Sep 1, 2026 French Glendon E. III President and CEO Sell 4,098 2.26 9,261
Sep 1, 2026 Rose Geoffrey Beran Chief Commercial Officer Sell 1,746 2.26 3,946
Sep 1, 2026 Rose Geoffrey Beran Chief Commercial Officer Sell 1,530 2.26 3,458
Sep 1, 2026 Rose Geoffrey Beran Chief Commercial Officer Sell 2,390 2.26 5,401
Sep 1, 2026 Rose Geoffrey Beran Chief Commercial Officer Sell 2,213 2.26 5,001
Sep 1, 2026 Lehman David Aaron General Counsel Sell 4,827 2.26 10,909
Sep 1, 2026 Lehman David Aaron General Counsel Sell 3,476 2.26 7,856
Sep 1, 2026 Lehman David Aaron General Counsel Sell 2,224 2.26 5,026
Sep 1, 2026 Lehman David Aaron General Counsel Sell 3,807 2.26 8,604

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?